Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Legubicin injection combination vs control in relapsed ovarian cancer and monotherapy in refractory choriocarcinoma
ChiCTR2500105421Phase 2Not yet recruiting
- Sponsor
- Union Hospital of Huazhong University of Science and Technology
- Start
- Jul 2025
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lecubicin in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC) and 1 more (6 cohorts), sponsored by Union Hospital of Huazhong University of Science and Technology. Primary endpoints: Imaging evaluation of cancer, Dose-limiting toxicity (DLT) occurrence and frequency and 2 more. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
lecubicin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)choriocarcinoma
Beyond the preview
Go deeper on ChiCTR2500105421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105421.